MedTrace Logo

Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

NCT07099157 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-01-02

No results posted yet for this study

Summary

This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.

Conditions

  • Herpes Zoster

Interventions

DRUG

Brivudine

brivudine 125 mg per dose, once daily, 7 days

DRUG

Famciclovir

orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Air Force Military Medical University, China

    collaborator OTHER

  • Beijing Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Xuanwu Hospital, Beijing

    collaborator OTHER

  • Peking University Third Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-25
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07099157 on ClinicalTrials.gov